Drugs / IMM0306S
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06535412 | Oct 2024 → Dec 2028 expected | systemic lupus erythematosus | ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-03-04 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Regulatory 宜明昂科阿沐瑞芙普α皮下制剂IMM0306S治疗系统性红斑狼疮IND获国家药监局批准，自免管线全面布局彰显创新实力 immuneonco.com ↗ |
| 2025-12-18 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Regulatory 宜明昂科阿沐瑞芙普α皮下制剂IMM0306S临床研究申请获受理，系统性红斑狼疮治疗迎新突破 immuneonco.com ↗
阿沐瑞芙普α（皮下注射制剂）IMM0306S用于治疗系统性红斑狼疮（SLE）的临床试验申请（IND）已正式获得国家药品监督管理局（NMPA）受理（受理号：CXSL2501092）。 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-03-04 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 宜明昂科阿沐瑞芙普α皮下制剂IMM0306S治疗系统性红斑狼疮IND获国家药监局批准，自免管线全面布局彰显创新实力 immuneonco.com ↗ |
| 2025-12-18 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 宜明昂科阿沐瑞芙普α皮下制剂IMM0306S临床研究申请获受理，系统性红斑狼疮治疗迎新突破 immuneonco.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMM0306S | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06535412 ↗ |
| Route | Subcutaneous | “subcutaneous IMM0306S” NCT06535412 ↗ |